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Therapeutic drug monitoringLong-term linezolid use is limited by mitochondrial toxicity-associated adverse events (AEs). Within a prospec-
tive, randomized controlled trial of linezolid to treat chronic extensively drug-resistant tuberculosis, we serially
monitored the translational competence ofmitochondria isolated fromperipheral blood of participants by deter-
mining the cytochrome c oxidase/citrate synthase activity ratio.We compared this ratiowith AEs associatedwith
mitochondrial dysfunction. Linezolid trough concentrations were determined for 38 participants at both 600mg
and 300 mg doses. Those on 600 mg had a signiﬁcantly higher risk of AE than those on 300 mg (HR 3·10, 95% CI
1·23–7 · 86). Mean mitochondrial function levels were signiﬁcantly higher in patients before starting linezolid
compared to their concentrations on 300 mg (P = 0·004) or 600 mg (P b 0·0001). Increasing mean linezolid
trough concentrations were associated with lower mitochondrial function levels (Spearman's ρ=−0.48; P =
0.005). Mitochondrial toxicity risk increased with increasing linezolid trough concentrations, with all patients
with mean linezolid trough N2 μg/ml developing an AE related to mitochondrial toxicity, whether on 300 mg
or 600mg. Therapeutic drug monitoring may be useful to prevent the development of mitochondrial toxicity as-
sociated with long-term linezolid use.
Published by Elsevier B.V.1. Introduction
Linezolid is a protein synthesis inhibitor approved by the U.S. Food
and Drug Administration for the treatment of vancomycin-resistant En-
terococcus faecium infections, nosocomial pneumonias, and skin and
skin structure infections. Linezolid binds to the 50S subunit of the bacte-
rial ribosome, competing with recognition of the incoming aminoacyl-
tRNA molecule that would normally bind to this site (Ippolito et al.,
2008). Mammalian mitochondrial ribosomes, unlike cytosolic ribo-
somes, are thought to have been symbiotically acquired from free-living
prokaryotes (Sagan, 1967). Although mammalian mitochondrialSC 3206, Bldg 33, Rm 2W20,ribosomes have evolved substantially from their prokaryotic progeni-
tors (Greber et al., 2014, 2015), in the region of the central loop of Do-
main V containing the cleft where linezolid (and the amino acid side
chains of charged tRNAs) binds, the rRNA is very conserved. Further ex-
perimental evidence that linezolid binds to this region of themammali-
an ribosome has been obtained (Leach et al., 2007). The use of linezolid
for longer than 2–3weeks is therefore limited by adverse events such as
bonemarrow suppression, lactic acidosis, and peripheral and optic neu-
ropathy that have been associated with the inhibition of mitochondrial
protein synthesis (De Vriese et al., 2006; McKee et al., 2006; Soriano et
al., 2005).
Linezolid has been used off-label in the treatment of drug-resistant
tuberculosis, with growing evidence for its efﬁcacy but with use limited
by these adverse events (Lee et al., 2012, 2015; Tang et al., 2015; Sotgiu
et al., 2012; Koh et al., 2012). In this analysis, we describe inmore detail
the adverse events associated withmitochondrial toxicity that occurred
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the extent of mitochondrial toxicity in association with linezolid dose
and trough concentrations.
2. Methods
2.1. Linezolid Clinical Trial
We conducted a prospective, randomized controlled trial of linezolid
for the treatment of chronic, extensively drug-resistant tuberculosis
(XDR-TB), as previously described (Lee et al., 2012). Patients failing
their best background treatment regimen for the previous 6 months
were randomized either to immediate or delayed (2 months) addition
of linezolid 600mg orally once daily to their failing regimen. The prima-
ry endpoint was time to sputum culture conversion on solid medium,
with data censored at 4 months. After sputum smear conversion or re-
ceipt of linezolid for 4months, therewas a second randomization either
to continue linezolid 600mg once daily or to reduce the dose to 300mg
once daily. The optimized background regimen was also continued and
additional drugs were permitted as needed. Patients were then follow-
ed to the end of therapy (about 2 years) plus one additional year for
ﬁnal treatment outcomes. This study was approved by the local institu-
tional review boards and by the U.S. National Institute of Allergy and In-
fectious Diseases and is registered at clinicaltrials.gov (NCT00727844).
For this analysis, only adverse events associated with mitochondrial
dysfunction – peripheral neuropathy, optic neuropathy, and bone mar-
row suppression – were included. Lactic acidosis did not occur in this
trial. Peripheral neuropathies were graded by the Subjective Peripheral
Neuropathy Score (SPNS) (McArthur, 1998) and SPNS grades ≥2 were
included in this analysis, unless the grade 2 predated linezolid
administration.
2.2. Pharmacokinetics
Blood for linezolid trough concentrations was collected in most pa-
tients at both 600 mg and 300 mg (unless the dose was never reduced
to 300 mg). The ratio of the average trough value at 600 mg compared
to 300 mg was computed as 2·27 and this factor was used to impute
300 mg trough values for those missing these data.
2.3. Mitochondrial Enzyme Assay
Blood for the mitochondrial enzyme assay was collected before
starting linezolid, then every two weeks from weeks 3–23, monthly
through month 7, and every 2 months thereafter. Additional blood
was also collected during drug pauses due to adverse events and for
two weeks after restarting linezolid. Mitochondria were isolated using
the Mitochondria Isolation Kit (MITOISO2, Sigma) from peripheral
bloodmononuclear cells prepared by Ficoll density gradient centrifuga-
tion. Spectrometric measurement of the activities of cytochrome c oxi-
dase, three subunits of which are translational products of
mitochondrial ribosomes (Lemberg, 1969; Attardi and Schatz, 1988),
and citrate synthase, a mitochondrial protein synthesized by cytosolic
ribosomes that serves as a reliable marker of mitochondrial content
(Attardi and Schatz, 1988; Srere, 1969; Garrabou et al., 2007), was per-
formed using the Cytochrome c Oxidase Assay Kit (CYTOCOX1,
Sigma) and the Citrate Synthase Assay Kit (CS0720, Sigma), respec-
tively. Enzyme activity was calculated as speciﬁc activity in μmole
thionitrobenzoic acid formed (for citrate synthase) or μmole
ferrocytochrome c oxidized (for cytochrome c oxidase) per minute
per mg of protein. Mitochondrial function, as an indicator of the
translational competence of mitochondrial ribosomes, was deﬁned
as the ratio of cytochrome c oxidase activity to citrate synthase activ-
ity. Due to the time needed to develop and optimize the mitochon-
drial function assay, however, mitochondrial function values were
not collected during the ﬁrst year of the study.2.4. Polymorphisms in Mitochondrial 16S rRNA
A portion of mitochondrial DNA corresponding to nucleotides 515–
3221 of the mitochondrial genome (GeneBank ID, NC_012920)
(Anderson et al., 1981) containing both the 12S and 16S rRNA se-
quences was ampliﬁed by polymerase chain reaction and subjected to
sequencing in both directions commercially (Solgent, Daejeon, S.
Korea). Sequence reads were compared to the reference sequence
(GeneBank ID, NC_012920) to identify single nucleotide polymor-
phisms (SNPs) using Sequencher software (Gene Codes Corp., Ann
Arbor, MI, USA).
2.5. Statistical Analyses
Baseline characteristics between those who did or did not develop
adverse events associated with mitochondrial toxicity were compared
using a two-sample t-test for continuous variables and Fisher's exact
test for binary variables. The main statistical analyses were conducted
based onCoxmodels for time-to-event analyses. Thesemodels can eval-
uate covariates that vary over time, such as mitochondrial function and
linezolid dose, and time-ﬁxed covariates, such as randomization arm.
The starting time for these analyses was based on two different points
in the study:
1. Time from initiation of linezolid 600 mg once daily;
2. Time from second randomization to linezolid 600 mg or 300 mg
dose, corresponding to patients who remained on linezolid (and in
the study) long enough to undergo this second randomization.
The association of mitochondrial function and dose was evaluated
using generalized estimating equations to account for correlation intro-
duced by clustered data (i.e., multiple observations contributed by
a single subject). Spearman's rank correlation coefﬁcient and a corre-
sponding p-valuewere estimated by randomly sampling a single obser-
vation per subject. Boxplots summarized the medians and interquartile
ranges of the mean mitochondrial function values for each subject at a
given dose.
2.6. Role of the Funding Source
The National Institutes of Health participated in study design, data
collection, analysis, interpretation of data, writing of the report, and
the decision to submit the paper for publication. The Republic of Korea
Ministry of Health andWelfare was not involved in any of these aspects
of this study. The corresponding author had full access to all of the data
in the study and had ﬁnal responsibility for the decision to submit for
publication.
3. Results
The baseline characteristics of the 38 participants who received li-
nezolid are listed in Table 1, according to the presence or absence of a
mitochondrial toxicity-associated adverse event. Overall, 23/38
(60·5%) developed an adverse event and 15/38 (39·5%) did not. Pa-
tientswhodeveloped an adverse event had similar baseline characteris-
tics to those who did not except that more were older (P = 0·01) and
fewer had received BCG vaccination (P = 0·03). Patients failing their
best background regimen for the previous sixmonthswere randomized
to add linezolid 600 mg daily immediately or after a delay of two
months while maintaining their existing (failing) treatment regimen.
Median time from linezolid start to ﬁrst adverse event was 237 days.
At sputum smear conversion or receipt of 4months of linezolid, patients
were randomized a second time either to remain on linezolid 600 mg
daily or to reduce to 300 mg daily. Median time to ﬁrst adverse event
after the second randomization was 92 days for patients on 600 mg
and beyond the observation period (N2 years) for those on 300 mg.
Those continuing on 600 mg had a signiﬁcantly higher risk of adverse
Table 1
Baseline characteristics of 38 subjects who received linezolid.
Characteristic⁎ Mitochondrial toxicity-related
adverse event
Yes (N = 23) No (N = 15)
Mean age, years (SD) 43·9 (2·0) 35·8 (2·2)
Male, no. (%) 14 (60·9%) 13 (86·7%)
Mean body mass index (SD) 20·6 (0·9) 19·3 (0·9)
Diabetes, no. (%) 10 (43·5%) 4 (26·7%)
BCG vaccination, no. (%) 16 (69·6%) 15 (100%)
Radiographic ﬁndings, no. (%)
Far advanced 19 (82·6%) 10 (66·7%)
Cavitation⁎⁎ 10 (43·5%) 7 (46·7%)
Bilateral 23 (100·0%) 14 (93·3%)
Median no. previous treatment episodes (IQR) 5·0 (3·0–7·0) 4·0 (3·0–7·0)
Adverse event, no. (%)
Peripheral neuropathy 13 (56·5%)
Optic neuropathy 6 (26·1%)
Myelosuppression 4 (17·4%)
⁎ There were no signiﬁcant differences at baseline between the two groups except for
age (P = 0·01) and BCG (P = 0·03). Continuous variables summarized by means were
tested using a two-sample t-test, while a continuous variable summarized using amedian
was tested usingWilcoxon's rank sum test. Categorical variableswere tested using Fisher's
exact test.
⁎⁎ Excludes 7 patients with data missing for cavitation.
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ﬁdence interval 1·23–7·86).
All subjects had blood drawn for mitochondrial function and linezo-
lid trough concentrations, of whom 26 had troughs taken under both li-
nezolid 600 mg and 300 mg doses, while 12 had only linezolid 600 mg
trough concentrations. Mean mitochondrial function levels wereFig. 1. Boxplot of subject-level mean mitochondrial function by linezolid dose. Mean mitochon
signiﬁcantly lower than for the same patients at baseline (pre-linezolid). Meanmitochondrial fu
on 300 mg daily. Note that the bars of the boxplots summarize the median and interquartile vsigniﬁcantly higher in patients before starting linezolid compared to
their concentrations on 300 mg (P = 0·004) or 600 mg (P b 0·0001)
and concentrations in patients on 300 mg were signiﬁcantly higher
than concentrations in patients on 600 mg (P = 0·0002; Fig. 1). Mean
mitochondrial function level correlated with the risk of an adverse
event. For example, a decrease in mitochondrial function of one stan-
dard deviation (i.e., a 0.04 drop) was associated with a doubling of the
risk of an adverse event after the second randomization or after linezo-
lid initiation (Table 2).
Mean linezolid trough concentrations were signiﬁcantly lower for
patients on the 300 mg dose compared to the 600 mg dose (P b
0·0001; Fig. 2A) andmean linezolid trough concentrations also inverse-
ly correlated with mean mitochondrial function levels, with increasing
linezolid trough concentrations associated with decreasing mitochon-
drial function levels (Spearman's ρ=−0·48; P = 0·005; Fig. 2B). Fi-
nally, mean linezolid trough concentrations directly correlated with
the risk of an adverse event, such that for each 1 μg/ml increase in linez-
olid trough, there was a 2-fold increase in the risk of an adverse event
(Table 2). This was true whether or not the risk was modeled from
the time of linezolid initiation or the time of second randomization.
Fig. 3 shows the time to adverse event from the time of linezolid start
(Fig. 3A) or second randomization (Fig. 3B), stratiﬁed bymean linezolid
trough concentration. All patientswith amean linezolid trough N2 μg/ml
developed an adverse event, whether on 300 mg or 600 mg, whereas at
trough b2 μg/ml, less than half developed an adverse event. There was
no correlation between linezolid trough concentration and type of
adverse event.
All patients were examined for polymorphisms in mitochondrial
16S rRNA but no associations were found between speciﬁc poly-
morphisms and mitochondrial toxicity-related adverse events
(Table 3).drial function values for patients receiving linezolid 300 mg daily and 600 mg daily were
nction for patients on linezolid 600mg daily was also signiﬁcantly lower than for patients
alues of the subject's mean values.
Table 2
Cox regression results from different starting times to the ﬁrst subsequent adverse event
(AE).
Baseline time for analysis: Hazard ratio (95% CI) Z-statistic P-value
Mean linezolid trough and risk of AE
Time from second randomization 2.00 (1.45, 2.77)⁎ 4.19 b0.001
Time from linezolid initiation 2.05 (1.50, 2.79)⁎ 4.52 b0.001
Time varying mitochondrial function and risk of AE
Time from second randomization 0.49 (0.30, 0.93)† −2.17 0.030
Time from linezolid initiation 0.53 (0.25, 0.93)† −2.21 0.027
⁎ Increased risk for each 1 μg/ml increase in linezolid trough concentration.
† Decreased risk for each 1 standard deviation (0.04) increase inmitochondrial function
level.
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This analysis of 38 pulmonary XDR-TB patients treated with linezo-
lid demonstrates the inverse association between linezolid trough con-
centrations and mitochondrial function, with higher trough
concentrations associated with lower mitochondrial function. Further-
more, lower (impaired) mitochondrial function and higher linezolid
trough concentrations also correlated with the development of mito-
chondrial toxicity-related adverse events. No speciﬁc genetic polymor-
phism in mitochondrial 16S rRNA was found to be associated with the
development of adverse events in our analysis.
The oxazolidinone antibiotics inhibit bacterial growth by binding to
50S ribosomal RNA thereby inhibiting bacterial protein synthesis. Like-
wise, because of the structural resemblance of bacterial ribosomes with
mitochondrial ribosomes, mitochondrial protein synthesis also appears
to be inhibited by oxazolidinone antibiotics, causingmitochondrial tox-
icity (Leach et al., 2007;McKee et al., 2006; Soriano et al., 2005;Narita et
al., 2007). Linezolid, the prototype drug of this class, is approved by the
U.S. FDA for the treatment of severe infections caused by resistant
Gram-positive bacteria and is relatively well tolerated when used for
the approved treatment duration of up to 4 weeks. When used for lon-
ger durations, however, adverse events associated with mitochondrial
toxicity manifest, including peripheral and optic neuropathy, lactic aci-
dosis, and bone marrow suppression (Narita et al., 2007; Beekmann et
al., 2008). The extent of this toxicity, resulting from the inhibition ofmi-
tochondrial protein synthesis, can be quantitated by measuring the mi-
tochondrial enzymatic activity of cytochrome c oxidase, which has been
shown to decrease with linezolid use and return to normal with linezo-
lid discontinuation (De Vriese et al., 2006; Soriano et al., 2005; Garrabou
et al., 2007; Nagiec et al., 2005). Mitochondrial function was therefore
deﬁned as the activity of cytochrome c oxidase, representing the extent
of mitochondrial protein synthesis, normalized to the activity of citrate
synthase, a surrogate marker of mitochondrial mass considering the
possible ﬂuctuation of mitochondrial mass with linezolid use
(Garrabou et al., 2007). Declining mitochondrial function then can be
demonstrated by declining cytochrome c oxidase activity per unit cit-
rate synthase activity. In our analysis, mitochondrial function correlated
inversely with both linezolid dose and linezolid trough concentration.
Patients with an average linezolid trough concentration above 2 μg/ml
nomatter thedose all developed adverse events related tomitochondri-
al toxicity.
One case–control study and several case reports, including a total of
7 patients, suggested an association between linezolid mitochondrial
toxicity and the mitochondrial ribosomal RNA polymorphisms
A2706G or G3010A (Palenzuela et al., 2005; Carson et al., 2007; Velez
and Janech, 2010; Del Pozo et al., 2014). In our analysis, we did not
ﬁnd any association between mitochondrial toxicity adverse eventsFig. 2.A:Mean linezolid trough concentration by linezolid dose.Mean linezolid trough concentr
that the bars of the boxplots summarize the median and interquartile values of the subject's m
There is a signiﬁcant inverse correlation such that highermean linezolid trough concentrations
summarize the median and interquartile values of the subject's mean values.and these or any other mitochondrial RNA polymorphism (Table 3).
All of our patients, whether they developed an AE or not, had the
A2706G polymorphism.
Newer oxazolidinones associated with a lower risk of mitochondrial
toxicity are being developed. Tedizolid is the second oxazolidinone ap-
proved by the FDA for severe infections caused by resistant Gram-posi-
tive bacteria and, in short-term studies, appears to have a lower side
effect proﬁle than linezolid (Burdette and Trotman, 2015). The reason
for this difference may be because tedizolid appears to have a shorter
mitochondrial binding half-life than linezolid and thus allows for a peri-
od ofmitochondrial recoverywith every dosing interval (Flanagan et al.,
2015). Long-term use of tedizolid in rats has not been associated with
adverse events, in contrast to linezolid (Schlosser et al., 2015; Wang et
al., 2014). Long-term studies of tedizolid in humans have not been
published.
In our analysis, we focused more on the risk of an adverse event fol-
lowing the second randomization because this was the only time pa-
tients were randomized to differing doses of linezolid, allowing a
more unbiased comparison of the risks of these differing doses. At the
same time, these patients may be a select group relative to the more
general set of patients enrolled at baseline because they demonstrated
improved tolerability of linezolid. Thus we also analyzed the risk of li-
nezolid from the time of linezolid start. Both analyses gave very similar
results.
There are some limitations to our analysis. First, because mitochon-
drial function values were not collected during the ﬁrst year of the
study, ﬁve mitochondrial toxicity-related adverse events were without
associated mitochondrial function values and therefore were not in-
cluded in the analysis. Regardless, this limitation does not affect the as-
sociation between linezolid trough concentration and adverse event.
Second, our pharmacokinetics data only included linezolid trough con-
centrations and did not include measurements to determine the daily
area under the plasma concentration-time curve (AUC24). However, li-
nezolid trough concentrations rather than peaks correlate linearly
with estimatedAUC24 (Pea et al., 2010). Linezolid trough concentrations
also correlate with mitochondrial toxicity-related AEs (Cattaneo et al.,
2013; Sousa et al., 2011) and correlate just as well as AUC24 (Pea et al.,
2012). Finally, although we did not ﬁnd any correlation between mito-
chondrial RNA SNPs and linezolid mitochondrial toxicity, our analysis is
limited by the small sample size.
Long-termuse of linezolid is associatedwith development of themi-
tochondrial toxicities of peripheral neuropathy, optic neuropathy, lactic
acidosis, and myelosuppression. Mitochondrial toxicity can be quanti-
ﬁed by measuring mitochondrial function and impaired mitochondrial
function is directly correlated with an increased risk of developing
these adverse events. This risk increases until, at least in our analysis,
all patients with an average linezolid trough concentration above
2 μg/ml developed an adverse event. If conﬁrmed by other analyses,
patients on long-term linezolid should have trough concentrations
measured periodically and have their linezolid dose adjusted to
maintain a trough concentration below 2 μg/ml. As tedizolid and other
second-generation oxazolidinones that appear to have a lower risk of
developing mitochondrial toxicity reach the market, therapeutic drug
concentration monitoring may no longer be necessary.Author Contributions
TS, KNO, LEV, SNC, and CEB designed the study. TS, ML, and YC col-
lected the data. TS, H-SJ, YP, VD, and LEV conducted the laboratory anal-
yses. LED, DF, JW, and YC analyzed the data. TS, LED, VD, DF, LCG, KNO,ationwas signiﬁcantly higher for patients on 600mg daily compared to 300mg daily. Note
ean values. B: Mean mitochondrial function level by mean linezolid trough concentration.
correlate with lowermeanmitochondrial function levels. Note that the bars of the boxplot
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Fig. 3. Time to adverse event from linezolid start (3A) or second randomization (3B) bymean linezolid trough concentration. All patientswith amean linezolid trough concentration N 2 μg/ml,
regardless of dose, developed a mitochondrial toxicity-related adverse event. 6 = patient on 600 mg dose. 3= patient on 300mg dose. Note: Five patients who reduced their linezolid dose
from 600 mg to 300 mg due to adverse events before the second randomization are not included.
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Table 3
Mitochondrial ribosomal RNA single nucleotide polymorphisms (SNP) and their associa-
tion with adverse events.
SNP Adverse event, N (%) Odds ratio (95% CI)
No Yes
A2706G No 0 0 –
Yes 10 (100·0) 27 (100·0)
A1736G No 9 (90·0) 25 (92·6) 0·72 (0·06–8·93)
Yes 1 (10·0) 2 (7·4)
A2833G No 10 (100·0) 26 (96·3) 1·19 (0·04–31·57)
Yes 0 1 (3·7)
C1734T No 10 (100·0) 26 (96·3) 1·19 (0·04–31·57)
Yes 0 1 (3·7)
C2772T No 10 (100·0) 26 (96·3) 1·19 (0·04–31·57)
Yes 0 1 (3·7)
C2835T No 10 (100·0) 26 (96·3) 1·19 (0·04–31·57)
Yes 0 1 (3·7)
C3206T No 9 (90·0) 25 (92·6) 0·72 (0·06–8·93)
Yes 1 (10·0) 2 (7·4)
G1719A No 10 (100·0) 26 (96·3) 1·19 (0·04–31·57)
Yes 0 1 (3·7)
G3010A No 6 (60·0) 20 (74·1) 0·52 (0·11–2·42)
Yes 4 (40·0) 7 (25·9)
Ins2150 No 9 (90·0) 26 (96·3) 0·35 (0·02–6·13)
Yes 1 (10·0) 1 (3·7)
T2483C No 10 (100·0) 26 (96·3) 1·19 (0·04–31·57)
Yes 0 1 (3·7)
T2626C No 10 (100·0) 26 (96·3) 1·19 (0·04–31·57)
Yes 0 1 (3·7)
1633T. Song et al. / EBioMedicine 2 (2015) 1627–1633YX, CEB, and RYC interpreted the data. RYC drafted the manuscript. All
authors reviewed and approved the ﬁnal version.
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